thebiostories

Phase 1 Clinical Trials of MK-7602: A Promising New Chapter in the Fight Against Malaria ⏱ In 30 Seconds ✓ MK-7602 is a first-in-class experimental antimalarial drug jointly developed by WEHI and MSD . ✓ It blocks two essential malaria parasite enzymes, plasmepsin IX and plasmepsin X . ✓ Phase 1 studies found that MK-7602 was generally well tolerated in healthy volunteers and reached blood concentrations predicted to have antimalarial activity. ✓ The results mark an important transition from nearly a decade of laboratory research to early clinical development. From Laboratory Discovery to Human Trials Every new antimalarial medicine begins with a simple question: Can scientists stay ahead of one of humanity’s oldest and most adaptable killers? For decades, malaria parasites have repeatedly evolved resistance to medicines that once transformed global malaria control. Each time a highly effective treatment has been introduced, the parasite h...